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Abstract
Background: Up-regulation of S100A7 (Psoriasin), a small calcium-binding protein, is associated with the
development of several types of carcinomas, but its function and possibility to serve as a diagnostic or prognostic
marker have not been fully defined. In order to prepare antibodies to the protein for immunohistochemical studies
we produced the recombinant S100A7 protein in E. coli. mRNA extracted from human tracheal tumor tissue which
was amplified by RT-PCR to provide the region coding for the S100A7 gene. The amplified fragment was cloned in
the vector pCR2.1-TOPO and sub-cloned in the expression vector pAE. The protein rS100A7 (His-tag) was expressed
in E. coli BL21::DE3, purified by affinity chromatography on an Ni-NTA column, recovered in the 2.0 to 3.5 mg/mL
range in culture medium, and used to produce a rabbit polyclonal antibody anti-rS100A7 protein. The profile of
this polyclonal antibody was evaluated in a tissue microarray.
Results: The rS100A7 (His-tag) protein was homogeneous by SDS-PAGE and mass spectrometry and was used to
produce an anti-recombinant S100A7 (His-tag) rabbit serum (polyclonal antibody anti-rS100A7). The molecular
weight of rS100A7 (His-tag) protein determined by linear MALDI-TOF-MS was 12,655.91 Da. The theoretical mass
calculated for the nonapeptide attached to the amino terminus is 12,653.26 Da (delta 2.65 Da). Immunostaining
with the polyclonal anti-rS100A7 protein generated showed reactivity with little or no background staining in head
and neck squamous cell carcinoma cells, detecting S100A7 both in nucleus and cytoplasm. Lower levels of S100A7
were detected in non-neoplastic tissue.
Conclusions: The polyclonal anti-rS100A7 antibody generated here yielded a good signal-to-noise contrast and
should be useful for immunohistochemical detection of S100A7 protein. Its potential use for other epithelial lesions
besides human larynx squamous cell carcinoma and non-neoplastic larynx should be explored in future.
Keywords: S100A7 (Psoriasin), Recombinant protein, Production of a polyclonal antibody, E. coli BL21::DE3, Mass
spectrometry
Background
Head and neck squamous cell carcinomas (HNSCC) are
among the most common types of neoplasias and their
relative incidence has increased recently due to the ris-
ing life expectancy of the population [1]. HNSCC are
tumors of epithelial origin which can involve the oral
cavity, pharynx and larynx. Their main risk factors are
exposure to alcohol and tobacco [2]. Changes triggered
in genes involved in the regulation of important cell
functions may result in disordered proliferation and the
invasion of other tissues [3]. As is the case for most
neoplasias, there are no specific biomarkers for HNSCC.
In a study of the serial analysis gene expression (SAGE)
of human larynx tumor tissue several differentially
expressed genes were identified, among them, the up-
regulation of the S100A7 gene [4] belonging to a family
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of calcium-binding proteins. S100A7 has been consid-
ered to be a marker for tumor progression in oral neo-
plasias [5], as well as in breast [6] and ovarian cancer
[7] on the basis of immunohistochemistry; however, its
expression in normal tissue appears to preclude its use
as a specific cancer marker [8].
The S100A7 protein, also called psoriasin, was
detected in keratinocytes of psoriatic epidermis. The
S100A7 gene is organized in 3 exons and consists of
306 base pairs, and the translated protein has 101
amino acids and a molecular mass of 11,457 Da calcu-
lated on the basis of amino acid composition [9]. The
protein S100A7 is a member of the S100 protein family
containing two calcium-binding domains denoted “2EF
hand”. Thus, the protein contains a calcium-binding
domain in the N-terminal region which includes an
additional three amino acids when compared to the
other S100 proteins, and a binding domain in the C-
terminal region containing the structural motif “EF
hand” [10]. S100 proteins have been implicated in a
variety of intracellular and extracellular functions and
are involved in regulation of protein phosphorylation,
transcription factors, Ca2+ homeostasis, the dynamics of
cytoskeleton constituents, enzyme activities, cell growth
and differentiation, and the inflammatory response. The
S100 protein family contains 21 members [11] that are
located within the S100 gene cluster in the q21 region
of chromosome 1 [12].
Because several lines of evidence suggested that
S100A7 might be a biomarker for tumor progression,
we prepared the recombinant protein and polyclonal
antibodies to it. At that time we were not aware of com-
mercially available antibodies.
In the present study, the rS100A7 (His-tag) protein
was expressed in E. coli BL21::DE3, purified by affinity
chromatography on an Ni-NTA column and character-
ized by SDS-PAGE, Western blot and mass spectrome-
try. The homogeneous rS100A7 (His-tag) protein was
used to produce the polyclonal antibody anti-rS100A7
which was applied to microarrays of tissues containing
human larynx squamous cell carcinoma and non-neo-
plastic tissues.
Results and discussion
Amplification and cloning of the S100A7 gene
Amplification of the S100A7 gene by PCR (Figure 1a)
and nested PCR (Figure 1b) was confirmed in 1.0% agar-
ose gel (w/v) electrophoresis by detection of the
expected 306 bp fragment (Figure 1). The fragment cor-
responding to gene S100A7 was sub-cloned in an
expression vector (pAE/S100A7) after cleavage with the
restriction enzymes XhoI and HindIII. The correct inser-
tion, identity and integrity of gene S100A7 were demon-
strated on the basis of DNA sequencing which
presented an identical sequence to that in GenBank
Accession number 002963 (data not shown). The
recombinant plasmid (pAE/S100A7) was then intro-
duced into E. coli BL21::DE3 for the expression of
recombinant S100A7 (His-tag) protein.
Expression and purification of the recombinant S100A7
(His-tag) protein
The expression of rS100A7 (His-tag) protein fused with
His-tag was carried out in E. coli BL21DE3. The highest
amount of recombinant proteins was obtained when the
IPTG inducer was not added to the culture medium.
The rS100A7 (His-tag) protein was present in inclusion
bodies which were denatured in 8 M urea before purifi-
cation with the Ni-NTA affinity column under denatur-
ing conditions. The yield of rS100A7 (His-tag) protein
was 2.0 to 3.5 mg/mL culture medium. Purified
rS100A7 (His-tag) protein (200 ng) was homogeneous
by 12.5% SDS-PAGE and Western blotting using the
anti-S100A7 (His-tag) polyclonal antibody described
here (Figure 2).
Identification of rS100A7 (His-tag) protein by mass
spectrometry
We did not try to remove the nonapeptide from
rS100A7 (His-tag). The rS100A7 (His-Tag) protein was
purified by SDS-PAGE, treated with trypsin and the
hydrolysate analyzed by MALDI-TOF-MS (Figure 3a).
Ions with the highest intensity were sequenced by CID-
MS/MS. The peptides identified by sequencing
accounted for 55% of the amino acid sequence of the
S100A7 protein acquisition number P31151, Swiss-Prot
data base (Figure 3b).
Figure 1 Electrophoretic profile of the DNA fragment
corresponding to the S100A7 gene after PCR amplification on
1.5% agarose gel (w/v). a, θX174 DNA ladder in kbp; b,
amplification of cDNA of tracheal head and neck squamous cell
carcinoma (HNSCC) tissue; c, nested PCR of amplification of the
DNA fragment, with the presence of the fragment of approximately
306 bp in both lanes; d, control (PCR without template).
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The protein rS100A7 (His-Tag) described here has a
nonapeptide, MHHHHHHLE, attached to its amino ter-
minus. The molecular mass of the intact protein deter-
mined by linear MALDI-TOF-MS (Figure 3c) was
12,655.91 Da compared to a calculated molecular mass
of 12,653.26 Da (delta = + 2.65 Da) (ExPasy Proteomics
Server, http://expasy.org). We never had the rS100A7
protein without the His-tag.
Western blot analysis of rS100A7 (His-Tag)
The gel in Figure 2, lane 1, shows that only a primary
component in the purified recombinant protein was
detected by the antibody or by Coomassie Blue staining
and that the mobility in SDS-PAGE corresponded to a
mass of approximately 11.5 kDa. A second component
in much lower concentration is visible at a higher mole-
cular weight and may be an oligomer.
Immunohistochemical analysis of the anti-S100A7 (His-
tag) polyclonal antibody using TMA
The tissues spotted on the TMA slide were immunos-
tained with the anti-recombinant S100A7 (His-tag) rab-
bit serum. Both neoplastic and non-neoplastic squamous
epithelium reacted with the polyclonal and commercial
monoclonal S100A7 antibody. Human S100A7 protein
was detected by the anti-recombinant S100A7 (His-tag)
rabbit serum (Figure 4).
The images of immunohistochemical reactions for the
target protein shown in Figure 4 illustrate the immunor-
eactivity of the polyclonal antibody: Figure 4a and 4b
show the negative controls (non-immune serum or
absence of secondary antibody). The anti-recombinant
S100A7 (His-tag) rabbit serum was able to detect both
neoplastic and non-neoplastic squamous epithelium at
1:12,000 dilution (Figure 4c-j). The staining score was 1
+ to 4+ with exclusive cytoplasm staining (C-F) and
both cytoplasm and nuclear staining (Figure 4g-j).
We have not systematically compared the protein
expression of S100A7 between normal and neoplastic
tissues or with the clinical and pathological characteris-
tics in detail. However, a preliminary analysis of the
results permitted us to determine variations in the levels
and location of the protein in neoplastic epithelia
obtained from HNSCC (Figure 4, panels g-j). The
human S100A7 protein is produced in oral tissues, with
cytoplasmic localization, during the early stages of the
disease and its expression increases with disease pro-
gression (cytoplasmic and nuclear localization) (Figure
4, panels g-j), suggesting its association with the pro-
gression and recurrence of HNSCC [8].
Conclusions
The polyclonal anti-rS100A7 antibody described here
provided a good signal-to-noise contrast and is suitable
for immunohistochemical detection of S100A7 protein.
However its reactivity with non-neoplastic squamous
epithelium precludes its use as a specific marker of neo-
plastic tissue. It may prove to be useful as a marker of
prognosis. Its potential use for other epithelial lesions
besides human larynx squamous cell carcinoma and
non-neoplastic larynx should be explored in further
studies.
Methods
Cloning the S100A7 gene
The open reading frame of the human S100A7 gene was
obtained by PCR using a cDNA template from tracheal
tumor tissue ("Projeto Genoma Clínico”, FAPESP and
Ludwig Institute for Cancer Research, Brazil) [13,14].
Primers containing cleavage sites for the restriction
enzyme XhoI (5’ ATGGATCCCTCGAGATGAGCAA-
CACTCAAG 3’) and HindIII (5’ ATAAGCTTT-
CACTGGCTGCCCCCGGAA 3’) were synthesized by
Invitrogen (Carlsbad, CA, USA). For PCR, 10 μg from
trachea tissue furnished by the human tissue cDNA
bank of the Regional Center for Hemotherapy of
Ribeirão Preto, University of São Paulo, was used. The
Figure 2 Expression and homogeneity of rS100A7 (His-tag)
protein. SDS-PAGE 12.5% electrophoresis of rS100A7 (His-tag)
protein. The protein was expressed in E. coli BL21::DE3 and purified
on an Ni-NTA affinity column. Lanes 1, 2 and 3, are the 1st, 2nd and
3 rd effluents of the column washed with 8 M urea. The gel was
stained with Coomassie blue G. Lane 4 is an extract of E. coli which
were not transformed (negative control). Lane 5 is a western blot
using anti-recombinant S100A7 (His-tag) rabbit serum at 1:5000
dilution. The arrows indicate the electrophoretic position
corresponding to rS100A7 (His-tag) protein.
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reaction mixture contained 1 mM dNTPs, 7.5 mM sense
and complementary primers, 1 U Platinum Taq DNA
polymerase in 50 mM Tris-HCl, pH 8.8, containing 500
mM KCl, 5 mM MgCl2 (Invitrogen) and 1% Tween 20
(Sigma, Saint Louis, MO, USA). PCR consisted of an
initial denaturation step of 5 min at 94°C, followed by
35 cycles of 40 s at 94°C (denaturation), 1 min of
annealing at 53°C (the specific annealing temperature
for the S100A7 gene) and 1 min at 72°C (extension). A
second nested PCR assay was then performed using 1 μl
of the reaction mixture described above and annealing
at 60°C. The amplified 306 bp product was purified on
1.0% (w/v) agarose gel using the Wizard SV Gel, PCR
Clean-Up System kit (Promega, Madison, WI, USA) and
inserted into the propagation vector pCR2.1-TOPO
using the TOPO-TA cloning kit (Invitrogen) according
to the manufacturer’s instructions. The construct was
introduced into E. coli DH5a by the thermal shock
Figure 3 Characterization of rS100A7 (His-tag) protein by mass spectrometry. a, MALDI-TOF-TOF mass spectrum of tryptic peptides derived
from rS100A7 (His-tag) protein. b, Mascot data obtained by analysis of the tryptic peptides shown in panel B. c, MALDI-TOF-TOF mass
spectrometric determination of the molecular mass of intact rS100A7 (His-tag) protein.
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method described by Sambrook and Russell [15] and the
recombinants were selected on solid Luria-Bertani (LB)
medium containing ampicillin (100 μg/ml). Plasmid
DNA was extracted with the plasmidPrep Mini Spin kit
(GE Healthcare, Little Chalfont, Buckinghamshire, UK)
according to the manufacturer’s instructions. The struc-
ture of the construct was confirmed by nucleotide
sequencing using the Thermocycle Sequencing BigDye
Terminator kit (Applied Biosystems, Carlsbad, CA,
USA) in an ABI Prism 377 automatic sequencer
(Applied Biosystems). The S100A7 fragment was
removed from the pCR2.1-TOPO vector by digestion
with the restriction enzymes XhoI and HindIII and
attached to the expression vector pAE, which contained
the 6xHis-tag peptide in the N-terminal region [16],
according to the protocol for the enzyme T4 DNA ligase
(Promega). The construct was introduced into compe-
tent E. coli DH5a cells with the Subcloning Efficiency™
Chemically Competent E. coli kit (Invitrogen). The
transformants were selected by PCR and plasmid DNA
was extracted as described by Sambrook and Russell
[15] and sequenced using the DYEnamic ET Dye Termi-
nator Sequencing kit (GE Healthcare) with the auto-
matic sequencer MegaBace™ 1000 (GE Healthcare).
This indicated that the insertion of the 306 bp fragment
corresponding to the S100A7 gene into the expression
vector pAE was correct. The sequence of the fragment
was identical to that deposited in GenBank as accession
number 002963.
Expression of rS100A7 (His-tag) protein
The E. coli BL21::DE3 host was transformed with the
vector pAE+S100A7 and plated onto selective medium.
A single colony was used for the inoculation of 200 ml
CircleGrow liquid medium containing 100 μg/mL ampi-
cillin into a 500 ml Erlenmeyer flask. The culture was
maintained at 37°C and stirred until it reached an absor-
bance of approximately 0.5 at 600 nm. Isopropyl-b-D-1-
thiolgalactopyranoside (IPTG) at 1 or 10 mM was added
to try to increase the amount of protein produced.
Purification of rS100A7 (His-tag) protein
E. coli BL21::DE3 cultivated in 500 ml of culture med-
ium was centrifuged at 5,000 g for 10 min and the pel-
lets were stored at -80°C. They were resuspended in 5
ml lysis buffer A (6 M GuHCl; 0.1 M NaH2PO4, 10 mM
Tris-Cl; pH 8.0) and maintained at 4°C for one hour
with shaking at 1,000 rpm. The lysate was centrifuged at
10,000 g for 30 min at 4°C (Eppendorf 5804 R) and 1.0
ml the supernatant was loaded onto an Ni-NTA Super-
Flow affinity chromatography minicolumn equilibrated
with buffer A (Qiagen, Hilden, Düsseldorf, Germany).
The remainder of the lysate (4.0 ml) was processed at
Figure 4 Immunohistochemistry tissue microarray (TMA) of
specimens of human larynx. Immunostaining of the S100A7
protein using the anti-recombinant S100A7 (His-tag) rabbit serum at
1:12,000 dilution. a and b show the negative control (absence of
primary antibody) for IHC. c and d, low staining (cytoplasm), spot
number (417595 T2) containing squamous cell carcinoma with a 1+
staining score (same spot number). e and f, moderate staining
(cytoplasm), spot number (426088 G2) containing squamous cell
carcinoma. g and h, strong staining (cytoplasmic and nuclear
localization); spot number (426088 T2) containing squamous cell. i
and j, strong staining (cytoplasmic and nuclear localization); spot
number (417739 T2) containing squamous cell carcinoma. The
panels with the letters A, C, E, G and were magnified ×100, and the
panels with the letters B, D, F, H and J were magnified ×400. The
brownish red region indicates the immunoreactivity of the rabbit
polyclonal antibody with the human S100A7 protein expressed in
the tissue of the larynx with neoplasia, after being labeled with a
chromogenic substrate (DAB) using the NovoLink Polymer
Detection System kit (Novocastra, Newcastle Upon Tyne, UK).
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1.0 ml/minicolumn. Each was centrifuged at 700 g for 2
min. After loading the minicolumn was washed with
600 μl buffer C (8 M urea; 0.1 M NaH2PO4, 10.0 mM
Tris-Cl; pH 6.3) and centrifuged at 700 g for 2 min two
times. The protein was eluted with 200 μl Buffer E (8 M
urea; 0.1 M NaH2PO4, 10.0 mM Tris-Cl; pH 4.5) and
centrifuged at 700 g for 2 min, three times.
The homogeneity of the recombinant S100A7 (His-
tag) protein (10 μg) was evaluated by 12.5% SDS-PAGE
[17]. The gel was stained with colloidal Coomassie blue
G-250 (Serva, Heidelberg, Germany) according to Neuh-
off et al. [18]. The amount of recombinant protein was
measured with a DC Protein Assay kit (Bio-Rad) based
on the method of Bradford [19] and determined by
absorbance at 595 nm in a Versa-Max microplate reader
(Molecular Devices, Sunnyvale, CA, USA).
Characterization of the recombinant S100A7 (His-tag) by
mass spectrometry
Recombinant S100A7 (His-tag) protein was characterized
after in situ trypsin digestion of the SDS-PAGE gel band
corresponding to 11.5 kDa. The band was cut from the
gel, destained with 0.1 M NH4HCO3 in 50% acetonitrile,
dehydrated with 100% acetonitrile, dried in a SpeedVac
(Savant Inc., Ramsey, MN, USA), and rehydrated with 20
μl 0.1 M NH4HCO3 containing 0.5 μg trypsin (Promega).
The protein was digested at 37°C for 24 h. The hydroly-
sate was desalted in a microtip filled with POROS 50 R2
resin (PerSeptive Biosystems, Foster City, CA, US) and
analyzed with a MALDI-TOF/TOF mass spectrometer
(Axima Performance, Kratos-Shimadzu Biotech, Manche-
ster, UK) equipped with a collision chamber for collision-
induced dissociation (CID), with helium as the collision
gas. The desalted hydrolysate was dissolved in 10 μl
matrix solution containing 5 mg/ml alpha-cyano-4-
hydroxycinnamic acid in 0.1% trifluoroacetic acid and
50% acetonitrile. Two microliters of the sample-matrix
solution were applied to the stainless steel MALDI plate
and allowed to evaporate. The mass spectrometer was
calibrated with a mixture of angiotensin II, ACTH frag-
ment 18-39, bradykinin fragment 1-7 and the oxidized B
chain of bovine insulin (Sigma). The PMF and MS/MS
spectra were analyzed with Mascot software V.2.2.4
(Matrix Science, London, UK) and compared with the
structure of S100A7 (His-tag) construct.
The molecular weight of the intact rS100A7 (His-tag)
protein was determined with MALDI-TOF/TOF-MS
operated in the linear mode after desalting with POROS
50 R2. The instrument was calibrated with insulin, cyto-
chrome C, chymotrypsin and bovine serum albumin.
Production of polyclonal antibody anti-rS100A7
The anti-recombinant S100A7 (His-tag) rabbit serum
was obtained according to standard protocols [20].
Briefly, two adult female New Zealand white rabbits
were immunized with 2.0 mg/animal of purified recom-
binant S100A7 (His-tag) protein emulsified in complete
or incomplete Freund’s adjuvant (Sigma) by subcuta-
neous or intramuscular injection, respectively. Before
immunization, blood was obtained from each animal to
prepare non-immune serum. The immunization effi-
ciency was analyzed by Western blotting and serum
samples were stored at -20°C.
Reaction of rabbit polyclonal antibody with recombinant
S100A7 (His-tag) protein under denaturing and reducing
conditions
Western blotting was performed after 200 ng of purified
recombinant S100A7 (His-tag) protein was submitted to
12.5% SDS-PAGE [17] and the protein was transferred
from the gel to a polyvinyldene fluoride (PVDF) mem-
brane in buffer containing 25 mM Tris, 192 mM gly-
cine, pH 8.3, and 10% methanol. A constant voltage of
35 V and 100 mA was applied. A PVDF membrane and
the Chromogenic Western Blot Immunodetection kit
(Invitrogen) were used according to manufacturer’s
instructions. The membranes were incubated separately
with the primary antibodies, i.e., the anti-recombinant
S100A7 (His-tag) rabbit serum at 1:5,000 dilution, and
the positive control monoclonal antibody S100A7
(Novocastra, Newcastle Upon Tyne, UK) at 1:1,000 dilu-
tion. Finally, the membranes were washed in MilliQ
water and incubated with the chromogenic substrate 5-
bromo-4-chloro-3-indolyl-1-phosphatase (BCIP) and
nitroblue tetrazolium (NBT). After protein labeling, the
membranes were washed with MilliQ water in order to
stop the reactions.
Interaction of the polyclonal antibody anti-rS100A7 with
tissue microarray (TMA)
The anti-recombinant S100A7 (His-tag) rabbit serum
was used for the detection of S100A7 by immunohisto-
chemistry in tissue samples arranged in a TMA. Repre-
sentative areas of tissues fixed in formalin and
embedded in paraffin were selected randomly and used
for the construction of a TMA block which contained
up to four spots each of non-neoplastic tissue (Malpigh-
ian epithelium) and of neoplastic tissue (squamous cell
carcinoma) from eight cases of neoplasias of the head
and neck region (larynx). The TMA experiment was
conducted using the polyclonal antibody at 1:2,000 to
1:16,000 dilutions. The anti-S100A7 monoclonal anti-
body (Novocastra) was used as a positive control at a
dilution of 1:50 to 1:200. All dilutions were incubated at
4°C for 16 h after antigen recovery under the following
conditions: incubation with 10 mM sodium citrate, pH
6.0, or incubation with 1 mM EDTA, pH 8.0, in a pres-
sure cooker for 40 min, or in the absence of antigen
Barbieri et al. BMC Research Notes 2011, 4:494
http://www.biomedcentral.com/1756-0500/4/494
Page 6 of 8
recovery. The reaction was amplified using the Novo-
Link Polymer Detection System kit (Novocastra) accord-
ing to manufacturer’s instructions. The reaction was
developed with the chromogenic substrate containing
0.10% diamine benzidine (Sigma, Saint Louis, MO, US),
0.06% hydrogen peroxide, and 1% dimethyl sulfoxide
(Labsynth) in PBS buffer. Sections containing TMA
were then counterstained with Harris hematoxylin and
rapidly immersed in 0.5% ammonium hydroxide. Immu-
noreactivity was scored as follows: absent (no color) or
positive (brownish red) present in up to 5% of the cells
of interest (+1), present in > 5% and ≤ 25% of the cells
of interest (+2), present in > 25% and ≤ 50% of the cells
of interest (+3), and present in > 50% of the cells of
interest (+4).
The controls were: positive - spots containing human
lung - and the negative control was without the primary
antibody.
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